Clinical Trial Update: Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes [Phase 2, Phase 3]

View source ↗

Summary

An update on fenofibrate for dyslipidemia and metformin-controlled diabetes from Phase 2/Phase 3 trials; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Type 2 Diabetes Mellitus

Drugs mentioned

• FENOFIBRATE (Fenofibrate)

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Dyslipidemia/Glucose Metabolism Disorder | Phase 2, Phase 3 | Status: COMPLETED